Back to Search Start Over

Cost‐effectiveness analysis of different treatment modalities in BCG‐unresponsive NMIBC.

Cost‐effectiveness analysis of different treatment modalities in BCG‐unresponsive NMIBC.

Authors :
Rieger, Constantin
Schlüchtermann, Jörg
Storz, Enno
Kastner, Lucas
Pfister, David
Heidenreich, Axel
Source :
BJU International; Oct2024, Vol. 134 Issue 4, p582-588, 7p
Publication Year :
2024

Abstract

Objective: Radical cystectomy (RC) is the standard of care (SOC) in BCG‐unresponsive NMIBC and is associated with a significant health‐related quality‐of‐life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed a Cost‐Effectiveness‐Analysis of those treatment modalities. Patients and Methods: We developed a Markov model from a payer's perspective drawing on clinical data of single‐arm trials testing intravesical gemcitabine/docetaxel and pembrolizumab in BCG‐unresponsive NMIBC, as well as clinical data from patients receiving hyperthermic intravesical chemotherapy HIVEC (n = 29) as intravesical salvage chemotherapy at our uro‐oncological centre in Cologne. Costs were simulated utilising a non‐commercial diagnosis‐related groups grouper, utilities were derived from comparable cost‐effectiveness studies. We used a Monte Carlo simulation to identify the optimal treatment, comparing the incremental cost effectiveness ratios (ICERs) at a willingness‐to‐pay threshold of €50 000 (euro)/quality‐adjusted life year (QALY). Results: Over a horizon of 10 years, gemcitabine/docetaxel, HIVEC, and pembrolizumab were associated with costs of €48 353, €64 438, and €204 580, as well as a gain of QALYs of 6.16, 6.48, and 6.00, resulting in an ICER of €26 482, €42 567, and €184 533 respectively, in comparison to RC with total costs of €21 871 and a gain of QALYs of 5.01. Monte Carlo simulation identified HIVEC as the treatment of choice under assumption of a WTP of <€50 000. Conclusion: Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost‐effective therapeutic options in BCG‐refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost‐effective assuming a price reduction of at least 70%. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14644096
Volume :
134
Issue :
4
Database :
Complementary Index
Journal :
BJU International
Publication Type :
Academic Journal
Accession number :
179808286
Full Text :
https://doi.org/10.1111/bju.16332